Viatris presents key ophthalmology study results at ASCRS 2026, advancing treatments for presbyopia and vision issues.

Viatris announced the presentation of four scientific abstracts at the 2026 ASCRS Annual Meeting, showcasing data from Phase 1 and Phase 3 studies on ophthalmic solutions for presbyopia and other vision conditions. Highlights include full results from the VEGA-3 Phase 3 trial of MR-141 for presbyopia, a Phase 1 study of varenicline nasal spray, and analyses of RYZUMVI® for reversing drug-induced pupil dilation and MR-142 for low-light vision disturbances post-refractive surgery. These presentations underline Viatris' commitment to innovative eye care solutions and support ongoing clinical education. Further details and educational events are available on the ASCRS website.